{
    "2019-07-21": [
        [
            {
                "time": "",
                "original_text": "仿制药价格体系加速重塑，药企迈向体系竞争时代|【光大医药·周报】",
                "features": {
                    "keywords": [
                        "仿制药",
                        "价格体系",
                        "重塑",
                        "药企",
                        "体系竞争"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "张金洋",
                        "机构医药持仓",
                        "2019Q2",
                        "2+X主线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}